BioUniversa is a biotechnology company which was created as a spin-off of the University of Salerno. BioUniversa operates in the field of molecular medicine and has developed an anti-BAG-3 antibody platform for therapeutic and diagnostic use for several clinical indications including oncology and, in particular, pancreatic cancer.

BioUniversa’s IP include several patents on the therapeutic and diagnostic use of BAG3-based tools. The company published many papers in peer-reviewed journals, including Nature Communications, Gut, PNAS, and others.

TT Venture invested in BioUniversa in October 2010, to support and develop the technology.